Focus Partners Wealth’s AbbVie ABBV Stock Holding History

Focus Partners Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,500	Closed	-$977K	–	1900
2024 Q4	$977K	Hold	5,500	–	–	﹤0.01%	1067
2024 Q3	$1.09M	Buy	+5,500	New	+$1.03M	﹤0.01%	923

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Focus Partners Wealth's ABBV Position: Q2 2026 in Review

Focus Partners Wealth increased its AbbVie (ABBV) stake by 3.9% in Q2 2026, buying an estimated $7.55M and bringing the position to 929,566 shares worth $234M. The position accounts for 0.24% of the portfolio, ranked #90.

Focus Partners Wealth first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Focus Partners Wealth held 929,566 shares of AbbVie worth $234M as of Q2 2026.
Focus Partners Wealth bought 35,099 AbbVie shares in Q2 2026, an estimated $7.55M.
AbbVie made up 0.24% of Focus Partners Wealth's portfolio in Q2 2026, its #90 holding.
Focus Partners Wealth first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.